ONL Therapeutics, Inc.
Ann Arbor, MI · Founded 2011 · CIK 0001611793 · Biotech · Private
Small-molecule and gene therapy therapeutics that inhibit Fas-mediated cell death signaling to prevent retinal cell loss in age-related macular degeneration and other retinal diseases
onltherapeutics.com →- Grants
- $3.1M
- 8 awards
- Sector median: 1
- Raised
- $111M
- 10 Form D · Sep 2024
- 25 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 0 granted · 40 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $501,810 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of ONL-101 for photoreceptor protection in retinal detach | $5,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical development of ONL-101 for photoreceptor protection in retinal detach | $30,875 | |
| Private capital raised | Form D · SEC | $916,161 | |
| Federal grant | Department of Health and Human Services · Phase II · De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials | $1,219,466 | |
| Private capital raised | Form D · SEC | $2,635,567 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD | $300,202 | |
| Private capital raised | Form D · SEC | $639,000 | |
| Private capital raised | Form D · SEC | $3,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD | $1,098,854 | |
| Private capital raised | Form D · SEC | $2,000,000 | |
| Private capital raised | Form D · SEC | $26,802,122 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD | $352,130 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD | $8,541 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD | $120,000 | |
| Private capital raised | Form D · SEC | $4,999,956 | |
| Private capital raised | Form D · SEC | $9,999,948 | |
| Private capital raised | Form D · SEC | $59,999,998 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1774 | Rescindo Therapeutics Inc | — | — |
| 1775 | ARES IMMUNOTHERAPY, INC. | — | — |
| 1776 | Calluna Pharma | — | — |
| 1777 | ONL Therapeutics, Inc. | — | $111M |
| 1778 | Alpine Bio | — | — |
| 1779 | Ravata Solutions, Inc. | — | — |
| 1780 | Cartography Biosciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- William BrinkerhoffDirector
- Bill BurnsDirector
- Rafael CastillaDirector
- Constance ChangExecutive Officer
- Loic CouraudDirector
- Felicia David-VisserDirector
- David EspositoDirector · Executive Officer
- Aaron FletcherDirector
- John FreshleyDirector · Executive Officer
- Christine GibbonsDirector
- Mark HooperDirector
- Jeffrey JamisonExecutive Officer
- Marian NakadaDirector
- Stella RobertsonDirector
- Michal SilverbergDirector
- David ZacksDirector · Executive Officer
Patents
- Peptide Compositions And Methods Of Useapplication
- Peptide Compositions And Methods Of Useapplication
- Sfasl For Inhibiting Rpe Cell Death And Associated Disordersapplication
- Methods And Compositions For Improving Visual Function In Ocular Diseases And Disordersapplication
- Methods And Compositions For Treating Ocular Disorders And Diseasesapplication
- Methods And Compositions For Improving Visual Function In Ocular Diseases And Disordersapplication
- Methods And Compositions For Treating Ocular Disorders And Diseasesapplication
- Methods And Compositions For Treating Ocular Disorders With Fasrapplication
- Methods And Compositions For Treating Ocular Lesionsapplication
- Methods And Compositions For Improving Visual Function In Ocular Diseases And Disordersapplication
- Methods And Compositions For Improving Visual Function In Ocular Diseases And Disordersapplication
- Methods And Compositions For Treating Rnfl Thinningapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.